Takeda Pharmaceutical Limited

4 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE: TAK) announced that it has awarded a total of USD 22.2 million to four new Global Corporate Social Responsibility (CSR) partners as part of the company's ongoing commitment to supporting climate-resilient health systems in low- and middle-income countries around the world and aligned with the company's purpose of better health for people, brighter future for the world. As climate change, extreme weather events and shifting.

4 days ago · reuters.com

Dr Reddy's ​Laboratories ‌said on ​Friday ​it signed a ⁠deal ​with ​Takeda Pharmaceutical Company ​for ​the promotion and ‌distribution ⁠of the Qdenga ​dengue ​vaccine ⁠in ​India.

6 days ago · defenseworld.net

Takeda Pharmaceutical (NYSE: TAK - Get Free Report) and Teva Pharmaceutical Industries (NYSE: TEVA - Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, profitability, institutional ownership and earnings. Volatility and Risk Takeda Pharmaceutical has a

8 days ago · seekingalpha.com

Takeda Pharmaceutical Company Limited (TAK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

8 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) under Priority Review for zasocitinib (TAK-279) for the treatment of adults with moderate-to-severe plaque psoriasis. Zasocitinib is an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, which demonstrated rapid, durable and consistent skin clearance in Phase 3 plaque ps.

13 days ago · businesswire.com

MALMO, Sweden & WILMINGTON, Del.--(BUSINESS WIRE)--Trialbee, the global patient recruitment leader reimagining clinical trials with AI, will present alongside Takeda at DPHARM 2026 taking place September 15–16 in Boston. During the event, Trialbee will unveil AI patient screening in its Honey Platform™, the next release on the Applied AI Recruitment roadmap it published earlier this year. Trialbee will also take an active role participating in a panel on AI technology for clinical sites in the.

20 days ago · zacks.com

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

25 days ago · reuters.com

The U.S. ​Food and ‌Drug Administration ​has approved a ​first-of-its-kind drug from ⁠Takeda ​Pharmaceutical and ​Protagonist Therapeutics to treat ​a ​rare blood cancer, the ‌health ⁠regulator said on ​Friday.

29 days ago · businesswire.com

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved the use of ORZEYFUL (oveporexton) for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults. ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and the only medicine indicated in Japan to treat the disease holistically rather than individual symptoms. The discovery of this new class of medicine o.

1 month ago · zacks.com

The consensus price target hints at a 26.4% upside potential for Takeda Pharmaceutical Co. (TAK). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.